Vectus Biosystems

Vectus Biosystems Debt / Assets

The Debt-to-Assets Ratio of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 0.14. In the previous year, Debt-to-Assets Ratio was 0.26 — a change of -43.97% (lower).

Debt / Assets

0.14

YoY

-43.97%

Last updated:

Debt-to-Assets Ratio of Vectus Biosystems is 2026 0.14 . Debt-to-Assets Ratio of Vectus Biosystems was 2025 0.26 . It decreases by -43.97% lower compared to the previous year.

The Vectus Biosystems Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2019
10.13 AUD
Jan 1, 2020
2.76 AUD
Jan 1, 2021
1.24 AUD
Jan 1, 2022
1.75 AUD
Jan 1, 2023
0.02 AUD
Jan 1, 2024
0.01 AUD
Jan 1, 2025
0.26 AUD
Jan 1, 2026
0.14 AUD
The Vectus Biosystems Debt / Assets history
YEARDebt / AssetsYoY
0.14-43.97%
0.26+1,689.49%
0.01-5.83%
0.02-99.14%
1.75+40.98%
1.24-54.96%
2.76-72.73%
10.13+117.97%
4.65+1,216.09%
0.35+32,976.82%
0.00+132.77%
0.00-99.30%
0.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Debt-to-Assets Ratio of Vectus Biosystems is 0.14 in 2026.

Debt-to-Assets Ratio of Vectus Biosystems changed from 0.26 to 0.14, representing a -43.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Vectus Biosystems

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Vectus Biosystems